Peptide impurity profiles: what HPLC and LC-MS can resolve

A peptide impurity profile should explain which related species the method can distinguish, how peaks are reported and what remains unresolved. Request that record alongside the chromatographic purity percentage when comparing custom synthesis batches or research materials.

Start with the material and the comparison you need

A catalogue entry can identify the target peptide while leaving the analytical comparison undefined. Before asking a laboratory to compare two batches, fix the sequence, terminal groups, chemical form and relevant modifications. Otherwise, a difference attributed to the manufacturing process may begin with two different material descriptions.

Write down the purchasing question. A team checking whether a replacement lot resembles a previously accepted lot needs a different review from a team investigating an unexpected secondary peak. The first question needs comparable batch records. The second may require additional characterisation of a particular species. Sending both requests as “confirm purity” leaves the laboratory to guess the decision.

Use an impurity map as a working record

Keep a row for each reported peak or unresolved group. Include the sample identifier, method revision, relative retention time, reported amount and identification status. Give tentative assignments their own status. An exact chemical name inferred from a mass difference should not silently become a confirmed identity in the purchasing specification.

What the current peptide guideline contributes

The EMA synthetic peptide guideline took effect on 1 June 2026. It distinguishes peptide-related species from non-peptide impurities and discusses co-elution and the possible need for additional independent analytical methods. Its scope concerns synthetic peptides used in medicinal products. It provides technical context for a research-material discussion; it does not approve a research catalogue or establish its release specification. [1]

ICH Q3A(R2) excludes peptides from its stated scope. Copying its small-molecule identification or qualification thresholds into a peptide order therefore needs a separate justification. Ask the responsible technical team which framework and application support the proposed limits. [2]

Match each analytical question to evidence

A deletion sequence lacks one or more intended amino-acid residues. Epimerisation changes stereochemistry at a residue; oxidation creates a chemical change of a different kind. These are different characterisation questions, so use explicit names when discussing candidate impurities. The EMA guideline describes such peptide-related species and degradation pathways. [1] Ask which candidates were investigated for the actual peptide and which assignments remain tentative.

Keep identity evidence separate from peak-area reporting

For an illustrative review, suppose a supplier labels a secondary signal “related impurity A” and a receiving laboratory labels it “unknown 2.” The first task is to reconcile the identifiers and methods. Treating the names as different substances before checking that connection creates a false batch difference. Conversely, matching names alone cannot establish that the laboratories measured the same species.

Compare batches using one reporting convention

Ask for the integration convention before subtracting two reported purity figures. Record how the method handles shoulders, unresolved groups and peaks below its reporting level. A chromatogram with a different cut-off may contain more listed peaks without demonstrating that the material changed.

ICH Q2(R2) links validation characteristics to the intended analytical purpose. For this review, the useful question is whether the procedure can selectively measure the impurity or group at the level the specification requires. A statement that an instrument is sensitive does not answer that question. [3]

Build the comparison from the same sample basis where possible. If the laboratory changes the procedure, request a bridge between the old and new records. Keep the explanation with the lot comparison so that a later purchaser does not mistake a method change for a new manufacturing trend.

What to include in a peptide impurity review request

• Exact material description and the lots being compared.
• Reason for the review, including any unexpected signal.
• Current chromatograms, method revisions and integration conventions.
• Peak or group assignments with confirmed and tentative statuses distinguished.
• Reporting limits, quantitation basis and any unresolved method limitations.
• The person responsible for agreeing the result and any follow-up work.

Use the guide to HPLC purity and peptide content when the issue concerns the denominator of a percentage. A new analytical package can be discussed through analytical services. For a sequence-specific project, include the review question with the custom peptide synthesis brief before agreeing which documents will accompany the batch.